Log in

Relevant bibliographies by topics / Epidermal growth factor Mutation (Biology) Adenocarcinoma

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Epidermal growth factor Mutation (Biology) Adenocarcinoma'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Epidermal growth factor Mutation (Biology) Adenocarcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Epidermal growth factor Mutation (Biology) Adenocarcinoma"

1

Siegelin, Markus D., and Alain C. Borczuk. "Epidermal growth factor receptor mutations in lung adenocarcinoma." Laboratory Investigation 94, no. 2 (2013): 129–37. http://dx.doi.org/10.1038/labinvest.2013.147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Suehisa, Hiroshi, Shinichi Toyooka, Katsuyuki Hotta, et al. "Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung." Journal of Clinical Oncology 25, no. 25 (2007): 3952–57. http://dx.doi.org/10.1200/jco.2007.11.8646.

Full text

Abstract:

Purpose Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas. Epidermal growth factor receptor (EGFR) mutations have been reported to be present in lung adenocarcinomas. The present study evaluated whether the EGFR status could be used as a biologic predictor of the outcome of adjuvant chemotherapy with uracil-tegafur. Patients and Methods The EGFR mutational status of 187 patients with resected lung adenocarcinomas was determined using a polymerase chain reaction–based assay for EGFR exons 19 and 21; the results

APA, Harvard, Vancouver, ISO, and other styles

3

Ding, Meng, Haixiu Liao, Nannan Zhou, Ying Yang, Shihe Guan, and Liwen Chen. "B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns." BioMed Research International 2020 (December 24, 2020): 1–8. http://dx.doi.org/10.1155/2020/8824805.

Full text

Abstract:

The cosignal molecule B7-H3 is gaining attention due to its abnormal expression and abundant signal transduction in many types of malignancies. B7-H3-induced signaling includes at least three cascades: PI3K/AKT, JAK2/STAT3, and Raf/MEK/ERK1/2, which are also involved in epidermal growth factor receptor- (EGFR-) triggered signaling in lung adenocarcinoma cells. However, the correlation between B7-H3-induced signaling and EGFR signaling, and between B7-H3-targeted immunotherapy and EGFR-targeted therapy in lung adenocarcinoma, remains to be elucidated. Herein we find that knockout of B7-H3 gene

APA, Harvard, Vancouver, ISO, and other styles

4

Peng, Min, Yi Ming Weng, Hua Li Liu, et al. "Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations." BioMed Research International 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/7181368.

Full text

Abstract:

Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor (EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly correlated with sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC). A mutation in exon 20 (T790M) is reportedly associated with resistance to EGFR-TKIs. However, few studies have focused on patients harboring double mutations in these 3 mutation sites. In this retrospective study, forty-five patients (45/2546, 1.7%) harbored double mutations of 1

APA, Harvard, Vancouver, ISO, and other styles

5

Wang, Hexiang, Hongwei Guo, Zeguo Wang, Bao Shan, and Jizheng Lin. "The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma." BioMed Research International 2019 (March 6, 2019): 1–8. http://dx.doi.org/10.1155/2019/9643836.

Full text

Abstract:

Objective. To retrospectively investigate computed tomographic (CT) quantitative analysis of ground-glass opacity (GGO) volume percentage and morphologic features of resected lung adenocarcinomas according to epidermal growth factor receptor (EGFR) mutation status and subtypes. Methods. Amplification refractory mutation system was used to detect mutations in the EGFR gene. Distribution of demographics and GGO volume percentage were performed according to EGFR mutation status and subtypes. Results. EGFR mutations were significantly more frequent in women (55.2% vs. 37.0%, p=0.001) and in never-

APA, Harvard, Vancouver, ISO, and other styles

6

Jänne, Pasi A., Jeffrey A. Engelman, and Bruce E. Johnson. "Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology." Journal of Clinical Oncology 23, no. 14 (2005): 3227–34. http://dx.doi.org/10.1200/jco.2005.09.985.

Full text

Abstract:

The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost universal presence in NSCLC tumors, therapeutic inhibition of EGFR has resulted in significant tumor regressions in only 10% to 20% of patients. Several investigations over the last 12 months have uncovered somatic mutations in EGFR that underlie the sensitivity to EGFR inhibitors. NSCLC tumors and cell lines with EGFR mutations are exquisitely sensitive to the EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitini

APA, Harvard, Vancouver, ISO, and other styles

7

Zhu, Wang-Yu, Hai-Feng Li, Ke-Xin Fang, et al. "Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma." Disease Markers 2018 (2018): 1–13. http://dx.doi.org/10.1155/2018/2942618.

Full text

Abstract:

Aims. The prognostic value of epidermal growth factor receptor (EGFR) mutations in the context of serum carcinoembryonic antigen levels remains controversial in T1 lung adenocarcinoma. Methods. Clinical and pathological characteristics, preoperational carcinoembryonic antigen levels, EGFR mutations, and disease-free and overall survival were analysed retrospectively in 573 pathological T1 patients in East China. Results. EGFR mutations were detected in 220 of 573 patients (38.4%). Patients with serum carcinoembryonic antigen levels ≥ 2.12 ng/mL had worse disease-free (P<0.001) and overall s

APA, Harvard, Vancouver, ISO, and other styles

8

Riza, Nur Marleta, and Daniel Maranatha. "Triple Mutation Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719S), 20 (T790M) and 21 (L858R) in a Male Patient with Lung Adenocarcinoma: A Case Report." Jurnal Respirasi 6, no. 1 (2020): 13. http://dx.doi.org/10.20473/jr.v6-i.1.2020.13-20.

Full text

Abstract:

Background: Lung cancer is one of the deadliest cancers in the world. The percentage of non small cell lung cancer (NSCLC) is about 80% of the incidence of lung cancer. The type of NSCLC, adenocarcinoma, is usually found in the presence of epidermal growth factor receptor (EGFR) mutations.Case. A male patient aged 70 years, an active smoker, works as a farmer. He has complained of shortness of breath, and chest pain for three months. There was no family history of suffering from malignancy. The cytology result of the right pleural fluid indicated adenocarcinoma. He was diagnosed with pulmonary

APA, Harvard, Vancouver, ISO, and other styles

9

Bell, Daphne W., Thomas J. Lynch, Sara M. Haserlat, et al. "Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials." Journal of Clinical Oncology 23, no. 31 (2005): 8081–92. http://dx.doi.org/10.1200/jco.2005.02.7078.

Full text

Abstract:

Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but the predictive value of these mutations has not been defined in large clinical trials. The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib. Patients and Methods We analyzed the frequency of EGFR mutations in lung cancer specimens from both the IDEAL and INTACT trials and compared it w

APA, Harvard, Vancouver, ISO, and other styles

10

Rybarczyk-Kasiuchnicz, Agnieszka, Rodryg Ramlau, and Katarzyna Stencel. "Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma." International Journal of Molecular Sciences 22, no. 2 (2021): 593. http://dx.doi.org/10.3390/ijms22020593.

Full text

Abstract:

Lung cancer is one of the most common malignant neoplasms. As a result of the disease’s progression, patients may develop metastases to the central nervous system. The prognosis in this location is unfavorable; untreated metastatic lesions may lead to death within one to two months. Existing therapies—neurosurgery and radiation therapy—do not improve the prognosis for every patient. The discovery of Epidermal Growth Factor Receptor (EGFR)—activating mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements in patients with non-small cell lung adenocarcinoma has allowed for the introduction

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Epidermal growth factor Mutation (Biology) Adenocarcinoma"

1

Tong, Wing-yee. "Studies on non-small cell lung cancer with EGFR mutation /." View the Table of Contents & Abstract, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31495333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tong, Wing-yee, and 唐穎儀. "Studies on non-small cell lung cancer with EGFR mutation." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B45010432.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

So, Kam-ting. "Mutations in epidermal growth factor receptor-related pathways in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43085313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

So, Kam-ting, and 蘇淦庭. "Mutations in epidermal growth factor receptor-related pathways in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43085313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dragana, Tegeltija. "Učestalost i tipovi mutacija receptora epidermalnog faktora rasta u invazivnim adenokarcinomima pluća." Phd thesis, Univerzitet u Novom Sadu, Medicinski fakultet u Novom Sadu, 2016. http://www.cris.uns.ac.rs/record.jsf?recordId=100677&source=NDLTD&language=en.

Full text

Abstract:

Receptor epidermalnog faktora rasta (EGFR) pripada porodici receptora protein-tirozin kinaze čija je aktivacija povezana sa proliferacijom malignih, invazijom, inhibicijom apoptoze, tumorskom angiogenezom i metastatskim &scaron;irenjem stoga ima važnu ulogu u karcinogenezi i tumorskoj progresiji. Aktivirane mutacije se odvijaju oko katalitičkog tirozin kinaza domena. Biopsijski, citolo&scaron;ki i hirur&scaron;ki uzorci se koriste u detekciji EGFR mutacija u momentu postavljanja dijagnoze adenokarcinoma ili karcinoma sa komponentom adenokarcinoma, najpouzdanije lančanom reakcijom polimeraze. Č

APA, Harvard, Vancouver, ISO, and other styles

6

Yu, Tan-Wen, and 尤丹文. "Pharmacological characterization of an epidermal growth factor receptor T790M mutation specific inhibitor (WZ8040)-resistant lung adenocarcinoma cells." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/81279517226709962729.

Full text

Abstract:

碩士<br>國立陽明大學<br>生物藥學研究所<br>103<br>Human non-small cell lung cancer (NSCLC) cells harboring epidermal growth factor receptor (EGFR) mutation are sensitive to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib (Iressa○R). However, lung cancer patients finally develop acquired resistance after treating with EGFR-TKIs for 9-12 months. EGFR T790M secondary mutation has been reported as the most common resistance mechanism. Recently, WZ8040, a third generation of EGFR-TKI has been introduced for targeting the EGFR T790M mutation. My thesis focused on studying the characteristics of WZ804

APA, Harvard, Vancouver, ISO, and other styles

7

Hsieh, Heng-Li, and 謝恒立. "CT Image Computer-aided Prediction of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Using Convolution Neural Network." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/ctezc8.

Full text

Abstract:

碩士<br>國立臺灣大學<br>資訊網路與多媒體研究所<br>105<br>Lung cancer is one of the leading causes of cancer in worldwide. The target-therapy is one of the effective and popular treatments for the patients with non-small cell lung carcinoma. The epidermal growth factor receptor (EGFR) testing is used to label gene mutation for predicting outcomes of the patients who receive treatment of target-therapy. However, the EGFR mutation testing is an invasive and time-consuming task. In this study, a computer-aided diagnosis (CAD) system based on deep learning is developed to perform the discrimination of EGFR mutation u

APA, Harvard, Vancouver, ISO, and other styles

8

Lin, Chang-Sheng, and 林昌生. "Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/qv7jt9.

Full text

Abstract:

博士<br>中山醫學大學<br>醫學研究所<br>106<br>Background The present study evaluated the prognostic value of the epidermal growth factor receptor (EGFR) mutation status, and excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression following intercalated tyrosine kinase inhibitor (TKI) therapy and platinum- and pemetrexed-based chemotherapies (subsequent second-line treatment) for patients with adenocarcinoma non-small-cell lung cancer (AC-NSCLC). Methods and Materials In total, 131 patients with AC-NSCLC were enrolled. The EGFR mutation status and ERCC1 and TS expressio

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Epidermal growth factor Mutation (Biology) Adenocarcinoma"

1

Kerr, David J., Daniel Haller, and Jaap Verweij. "Principles of chemotherapy." In Oxford Textbook of Cancer Biology, edited by Francesco Pezzella, Mahvash Tavassoli, and David J. Kerr. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198779452.003.0028.

Full text

Abstract:

Systemic cancer treatment stems initially from empirically discovered DNA synthesis inhibitors, which either deplete the cell of nucleotides, induce cross-link, or cause DNA single and double strand breaks or impair the cellular machinery of DNA repair, using mechanistically diverse drugs. A period of enlightenment followed, with anticancer drug development driven by an increased understanding of enzymes and pathways involved in cell signalling, control of angiogenesis, and epigenetics. This provided a parallel path towards precision cancer medicine where specific drugs can be targeted to patients with particular mutations. These include point mutations in RAS, which are used to exclude colorectal cancer patients from being treated with epidermal growth factor inhibitors; chromosomal translocations encoding fusion proteins which are cancer specific and serve as novel drug targets (e.g. BCR/ABL and imatinib, or EML4-ALK fusion oncogene and crizotinib). More recently, there has been a reanimation of immune approaches to cancer therapy with the clinical introduction of immune checkpoint inhibitors, designer T cells, and patient-specific antitumour vaccines. What next? It may be that next-generation sequencing provides an endless stream of so-called actionable mutations that permits tailored application of mutation-specific drugs, but so far there is little evidence of clinical benefit from such therapies.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Epidermal growth factor Mutation (Biology) Adenocarcinoma"

1

Cabrita, B., Cipriano, T. Amaro, L. Cirnes, H. Magalhães, and F. Estevinho. "A Long-Survival Patient with Advanced Lung Adenocarcinoma with the Epidermal Growth Factor Receptor T790M Mutation." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sekine, Akimasa. "Characteristics Of Metastatic Brain Tumor In Patients With Lung Adenocarcinoma With Mutation Of Epidermal Growth Factor Receptor Gene." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lai, Yi-Ling, Shin-Sheng Yuan, Hsuan-Yu Chen, Sung-Liang Yu, Ker-Chau Li, and Pan-Chyr Yang. "Abstract 3882: The comparison of genomic instability between epidermal growth factor receptor(EGFR) mutation status of lung adenocarcinoma." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3882.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Huang, Chung-Jen, and Wen-Hui Ku. "The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4250.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Wen-Chien. "Abstract 2001: Caffeic acid phenethyl ester inhibits growth of human lung adenocarcinoma cells with an epidermal growth factor receptor T790M mutation susceptible property." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Castañon Perez, Rosa Abril, Gustavo Gutiérrez Herrero, Haizea Álvarez Martínez, et al. "Clinical and computed tomography features (CT) of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) status." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!